Outset Medical, Inc.
Outset Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $119.5 million, up 5.09% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 6.73%, free cash flow fell 90.5% and total debt rose 4.20%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow OM
Outset Medical, Inc. (OM) Piotroski F-score
Outset Medical, Inc.'s Piotroski F-score for fiscal 2025 is 6 out of 9: 6 of nine tests of profitability, leverage and efficiency passed, up from 5 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 6 | 1.00 |
| FY2024 | 5 | 2.00 |
| FY2023 | 3 | 0.00 |
| FY2022 | 3 | (2.00) |
| FY2021 | 5 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (30.23%) | (43.41%) | Fail | 0 |
| Positive operating cash flow | (46.33m) | (116.30m) | Fail | 0 |
| Rising return on assets | (30.23%) | (43.41%) | Pass | 1 |
| Cash flow above net income | 35.33m | 11.67m | Pass | 1 |
| Falling long-term leverage | 0.36 | 0.67 | Pass | 1 |
| Rising current ratio | 6.67 | 5.69 | Pass | 1 |
| No new shares issued | 15,211,000 | 3,463,000 | Fail | 0 |
| Rising gross margin | 39.13% | 33.92% | Pass | 1 |
| Rising asset turnover | 0.44 | 0.39 | Pass | 1 |
| Piotroski F-score | Mixed | 6 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| OM Outset Medical, Inc. | 6 |
| APYX Apyx Medical Corporation compare | 4 |
| ZOMDF Zomedica Corp. compare | 4 |
| LUCD Lucid Diagnostics Inc. compare | 4 |
| SERA Sera Prognostics, Inc. compare | 4 |
| HYPR Hyperfine, Inc. compare | 4 |
| LUNG Pulmonx Corporation compare | 3 |
| ECOR electroCore, Inc. compare | 3 |
| LNSR LENSAR, Inc. compare | 3 |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover